Impact of Chronic Disease Prevalence on Genomic Biomarker Market SizeGrowth Driver: Leading Transformation in the Genomic Biomarker Market Sizein 2025

How Are the key drivers contributing to the expansion of the genomic biomarker market?
The escalating presence of enduring illnesses is projected to fuel the expansion of the genomic biomarker Market Sizein the future. These chronic diseases are long-term health concerns that persistently retain over periods, often signifying gradual progression. The heightened presence of such chronic diseases is linked to aging populations and incrementing instances of lifestyle-related complications such as obesity and diabetes. Genomic biomarkers allow for targeted and customized prevention plans for chronic diseases by identifying genetic inclinations and adapting interventions accordingly. By utilizing this proactive approach, this assists in lowering the presence of these diseases by identifying at-risk individuals before the illness onset. For example, data from the World Health Organization (WHO) in September 2023, a Switzerland-based intergovernmental organization, indicates that each year globally there are 41 million deaths, corresponding to 74% of all deaths being attributed to chronic diseases. These include 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from respiratory diseases, and 2.0 million from diabetes. Thus, the escalating presence of such chronic diseases propels the growth of genomic biomarkers.

Get Your Genomic Biomarker Market SizeReport Here:
https://www.thebusinessresearchcompany.com/report/genomic-biomarker-global-market-report

What growth opportunities are expected to drive the genomic biomarker market's CAGR through 2034?
The size of the genomic biomarker Market Sizehas been expanding swiftly over the recent years. It is projected to surge from a valuation of $8.4 billion in 2024 to $9.9 billion in 2025, showcasing a compound annual growth rate (CAGR) of 18.0%. Factors contributing to the growth during this past course include an increase in understanding of genetic disorders, amplified demand for targeted treatments, growth in the usage of big data in the genomics field, the expansion of global genomic databases and an uptick in biomarker-oriented clinical trials.

In the forthcoming years, the for genomic biomarkers is projected to experience a significant expansion. It's anticipated that the Market Sizewill expand to $18.93 billion by 2029, with a compound annual growth rate (CAGR) of 17.6%. The surge in the projected timeframe is primarily driven by increased concentration on accessible personalized medicines, escalating incidences of cardiovascular conditions, growing patient count with neurological disorders, heightened investment in genomic studies, and the rise in the acceptance of personalized nutrition. Leading trends in the predicted timeframe encompass technological evolution, digital health, artificial intelligence, machine learning, and personalized medicine.

Get Your Free Sample Now - Explore Exclusive Market SizeInsights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20557&type=smp

What are the emerging trends shaping the future of the genomic biomarker market?
Key players in the genomic biomarker industry are putting their efforts into the creation of improved products like advanced liquid biopsy assays which facilitate comprehensive genomic profiling of solid tumors. Liquid biopsy assays, tests which examine genetic material from blood samples (most commonly circulating tumor DNA or ctDNA), are used to detect and track cancer. They also provide critical information regarding specific genetic mutations, gene expression profiles, and other genetic changes related to cancer. For example, in November 2023, Illumina Inc., an American biotech company, introduced an innovative liquid biopsy assay called the TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). This product makes it possible to conduct comprehensive genomic profiling of solid tumors more effectively. It heightens analytical sensitivity by identifying low-frequency variants with just 20 ng of cell-free DNA, reducing the amount needed from 30 ng. The TSO 500 ctDNA v2 produces results in less than four days, significantly improving the speed of genomic profiling when compared to older methods. The process is more streamlined and the introduction of future automation will ease lab integration and increase operational efficiency.

Which growth-oriented segments of the genomic biomarker Market Sizeare leading the industry's development?
The genomic biomarker Market Sizecovered in this report is segmented -

1) By Type: Predictive Biomarkers, Prognostic Biomarkers
2) By Disease Indication: Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, Other Disease Indications
3) By Validation: Analytical Validation, Clinical Validation, Clinical Utility
4) By End-User: Hospitals, Diagnostic Centers, Research Laboratories, Other End Users

Subsegments:
1) By Predictive Biomarkers: Genetic Biomarkers For Disease Susceptibility, Pharmacogenomic Biomarkers For Drug Response, Early Detection Biomarkers For Disease Prediction, Biomarkers For Treatment Response Prediction
2) By Prognostic Biomarkers: Biomarkers For Disease Progression, Biomarkers For Outcome Prediction, Survival And Recurrence Biomarkers, Biomarkers For Treatment Efficacy And Prognosis

Unlock Exclusive Market SizeInsights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20557

What regions are leading the charge in the genomic biomarker market?
North America was the largest region in the genomic biomarker Market Sizein 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic biomarker Market Sizereport are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What companies are at the forefront of innovation in the genomic biomarker market?
Major companies operating in the genomic biomarker Market Sizeare Pfizer Inc., Roche Diagnostics, Thermo Fisher Scientific Inc., Merck KGaA, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Foundation Medicine Inc., QIAGEN N.V., Almac Group Ltd., Myriad Genetics Inc., Invitae Inc., Guardant Health Inc., Novogene Inc., Twist Bioscience Corp., NanoString Technologies Inc., Quanterix Corp., Personalis Inc., GENEWIZ Inc., Agena Bioscience Inc., Creative Diagnostics Ltd., OncoDNA SA, Genome Life Sciences Ltd., Epigenomics AG.

Customize Your Report - Get Tailored Market SizeInsights!
https://www.thebusinessresearchcompany.com/customise?id=20557&type=smp

What Is Covered In The Genomic Biomarker Global Market SizeReport?

• Forecast: Examine the genomic biomarker across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the genomic biomarker Market Sizefor a structured understanding.
•Key Players Overview: Analyze major players in the genomic biomarker market, including their Market Sizevalue, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the genomic biomarker market.
•Segment Contributions: Evaluate how different segments drive overall growth in the genomic biomarker market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the genomic biomarker market.
•Industry Challenges: Identify potential risks and obstacles affecting the genomic biomarker market.
•Competitive Landscape: Review strategic developments in the genomic biomarker market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.